MedTech startup Bioscan Research has raised $1 million in a seed funding round led by Unicorn India Ventures. The company said the capital will be used to expand its market presence, secure regulatory approvals, upgrade its products and develop new intellectual property.
Founded in 2017 by Anupam Lavania and Shilpa Malik, Bioscan Research develops technology for the early detection of traumatic brain injuries. Its flagship product, CEREBO, is a machine learning-powered near-infrared spectroscopy (NIRS) device designed to assist clinicians in detecting intracranial injuries, including in patients without visible symptoms, to support earlier diagnosis and intervention.
Co-founders of Bioscan Research said, “We harness light to reveal what the eyes can’t see giving doctors clarity, patients hope, and technology a heart. More than 50 million suffer from traumatic brain injury each year and 50-90% of patients with mild traumatic brain injury go unidentified. With this current round, we will be able to upgrade our product and bridge the limitations of traditional tools and provide urgent care in India and internationally.”
In the last 12 months the company has witnessed 5x growth and is redefining how critical conditions are identified—enabling faster clinical decisions, improved outcomes, and more accessible care worldwide
Anil Joshi, Managing Partner, Unicorn India Ventures said, “We have been investing in highly innovative medtech companies quite consistently as we believe the healthcare industry still has a big gap to address in countries like India. We believe the market is huge and the research is evident on how people are suffering from head injuries and brain trauma every year. It is time to bring the correct technology that will diagnose early symptoms and understand what the patient is suffering from.
“Bioscan Research is making it possible to detect intra-cranial haemorrhage non-invasively. The company has witnessed progress in the last 12 months and has upgraded its technology solutions. Hence, we believe the market opportunity is huge and the company has built the right momentum to capitalise on this segment,” Joshi said.
Over the next 12 months the company’s goal is to grow 3x and plans to expand in India and overseas markets.
